GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Change In Payables And Accrued Expense

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Change In Payables And Accrued Expense : $-0.81 Mil (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Change In Payables And Accrued Expense?

Parnell Pharmaceuticals Holdings's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2018 was $-0.81 Mil. It means Parnell Pharmaceuticals Holdings's Accounts Payable & Accrued Expense declined by $0.81 Mil from Dec. 2017 to Dec. 2018 .

Parnell Pharmaceuticals Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2018 was $-0.81 Mil. It means Parnell Pharmaceuticals Holdings's Accounts Payable & Accrued Expense declined by $0.81 Mil from Dec. 2017 to Dec. 2018 .


Parnell Pharmaceuticals Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Change In Payables And Accrued Expense Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Change In Payables And Accrued Expense
Get a 7-Day Free Trial 2.04 0.76 0.76 -1.20 -0.81

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Change In Payables And Accrued Expense Get a 7-Day Free Trial 2.04 0.76 0.76 -1.20 -0.81

Parnell Pharmaceuticals Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnell Pharmaceuticals Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.